Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

The Breast Cancer Epigenomics Track Hub

View ORCID ProfileGiovanna Ambrosini, Andrea Agnoletto, View ORCID ProfileCathrin Brisken, View ORCID ProfilePhilipp Bucher
doi: https://doi.org/10.1101/2022.05.01.490187
Giovanna Ambrosini
1Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
2Bioinformatics Competence Center (BICC), UNIL/EPFL Lausanne
3SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giovanna Ambrosini
Andrea Agnoletto
1Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathrin Brisken
1Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cathrin Brisken
  • For correspondence: cathrin.brisken@epfl.ch philipp.bucher@epfl.ch
Philipp Bucher
1Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland
3SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philipp Bucher
  • For correspondence: cathrin.brisken@epfl.ch philipp.bucher@epfl.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Background Pioneering research has shown that high-throughput epigenomics assays such as ChlP-seq and ATAC-seq are applicable to patient-derived breast tumor samples. A host of public data has been accumulated since then, which are potentially of high value for basic research as well as personalized medicine. Such data sets constitute encyclopedias of biological knowledge. However, their impact has so far been limited by access obstacles, especially with regard to extraction and visualization of small portions of data that could potentially answer specific questions arising in a research context.

Results We developed the breast cancer epigenomics track hub (BC hub), a resource intended to make it easy for occasional users to find, access and view data of their interest. The BC hub harbors ChIP-seq, ATAC-seq and copy number data from breast tumors, normal breast cells, patient-derived xenografts and breast cancer cell lines in a genome browsable track format. The tracks can be accessed via hyperlinks that automatically configure customized views for different interest groups. Here, we present a detailed description of the resource and informative use cases illustrating its potential in answering specific biological questions.

Conclusions We show that track hubs constitute a powerful way of bringing epigenomics data to the user who could benefit from them. The examples presented highlight the added-value of joint visualization of breast cancer data from different sources. The proof-of-concept provided here exemplifies and underscores the importance of efforts to make biological data FAIR (findable, accessible, interoperable and reusable), and may serve as an encouragement of similar bottom-up initiatives in other research fields. The BC hub is freely accessible at https://bchub.epfl.ch.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 01, 2022.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Breast Cancer Epigenomics Track Hub
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Breast Cancer Epigenomics Track Hub
Giovanna Ambrosini, Andrea Agnoletto, Cathrin Brisken, Philipp Bucher
bioRxiv 2022.05.01.490187; doi: https://doi.org/10.1101/2022.05.01.490187
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The Breast Cancer Epigenomics Track Hub
Giovanna Ambrosini, Andrea Agnoletto, Cathrin Brisken, Philipp Bucher
bioRxiv 2022.05.01.490187; doi: https://doi.org/10.1101/2022.05.01.490187

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cancer Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4384)
  • Biochemistry (9609)
  • Bioengineering (7103)
  • Bioinformatics (24896)
  • Biophysics (12631)
  • Cancer Biology (9974)
  • Cell Biology (14372)
  • Clinical Trials (138)
  • Developmental Biology (7966)
  • Ecology (12124)
  • Epidemiology (2067)
  • Evolutionary Biology (16001)
  • Genetics (10936)
  • Genomics (14755)
  • Immunology (9880)
  • Microbiology (23697)
  • Molecular Biology (9490)
  • Neuroscience (50924)
  • Paleontology (370)
  • Pathology (1541)
  • Pharmacology and Toxicology (2686)
  • Physiology (4023)
  • Plant Biology (8673)
  • Scientific Communication and Education (1511)
  • Synthetic Biology (2402)
  • Systems Biology (6444)
  • Zoology (1346)